[ad_1]
Vanderbilt vaccine researchers are recruiting adult volunteers in a Phase II clinical trial sponsored by the National Institutes of Health (NIH) to study a new-generation pertussis vaccine that can protect people from whooping cough.
The vaccine, BPZE1, is a live attenuated form of pertussis bacteria. BPZE1 is administered as a fog in the nose rather than under the arm. ILiAD Biotechnologies, LLC (ILiAD) provides the vaccine.
Buddy Creech, MD, MPH, director of the Vanderbilt Vaccine Research Program, said that administering the vaccine through the nose, instead of giving a traditional vaccine, could more closely mimic what we're seeing in a natural infection.
"It makes sense that when we can, we try to deliver vaccines to the body where we see the germ for the first time. For whooping cough, that's the nose, "Creech said. "We believe that the vaccine will not only give an immune response in the blood, as normally seen with a shot, but also a response to the nose."
"What we're learning is that the current vaccine is a good way to prevent diseases, but other vaccines may have a longer shelf life and better prevent the germ from being completely carried in the nose or pbaded from one person to "he said.
The Vanderbilt Vaccine Research Program invites healthy volunteers between the ages of 18 and 49 to participate in the study. NIH's National Institute of Allergy and Infectious Diseases (NIAID) sponsors the study through the Vanderbilt Vaccine Assessment and Treatment Unit (VTEU).
Source: Vanderbilt University Medical Center
Source link
